Recall archive / FDA drug enforcement
Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York... — FDA record D-0575-2025
Reported ongoing
Status as reported in the agency record. FDA warns that enforcement status may not track the current recall lifecycle; check the current official notice.
Source date Jul 29, 2025. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
What the record says
- Product
- Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, Distributed by: Pfizer Inc., New York, NY 10017, Made in Austria, NDC 60793-851-01.
- Reason
- Subpotent drug
- Classification
- Class II
- Recalling firm
- Pfizer
- Quantity
- 29, 004 bottles
- Agency-reported status
- Ongoing
- Source record identifier
- D-0575-2025
What the recall classes mean. Classification is an agency assessment, not individual medical advice.
Lot and product identifiers
| Label field | Details supplied by the agency |
|---|---|
| Lot, code or applicability | Lot #: 24C11, Exp 2/28/2026. |
Match all identifying details in the current notice. A brand name alone is not enough.
Distribution
Within U.S
No US distribution state could be established from this record. Check the official notice.
Dates in the source
- Report date
- Aug 20, 2025
- Recall initiation date
- Jul 29, 2025
- Center classification date
- Aug 8, 2025
FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.